Drugs / RO4602522
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02104648 | Apr → Aug 2014 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01701089 | Sep 2012 → May 2013 | Alzheimer disease 5 | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01625806 | Jul → Dec 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01631422 | Jun 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO4602522 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01631422 ↗ |
| Action | Inhibit | “inhibition of brain MAO-B by RO4602522” NCT01701089 ↗ |
| Route | Oral | “single oral dose” NCT01625806 ↗ |